Scientists at Cancer Research UK Scotland Institute and University of Glasgow identify a new pathway for delivering antisense oligonucleotides (ASOs) into cells, enhancing the effectiveness of ASO-based therapy for pancreatic cancer and other diseases. The researchers found that ASOs enter cells via endocytosis and bind to specific rec...
A team of researchers has developed chimeric allergen receptors that can suppress the immune system's response to common allergens, reducing or preventing asthma symptoms in mice. The technique could eventually be used to treat a wide variety of allergies in humans.
Researchers developed genetically engineered CAR T cells specifically targeting bladder cancer cells and delivered them directly to the bladder via a catheter. This approach shows promise in controlling bladder tumors in mice and may be effective in humans, offering an alternative to life-altering procedures like bladder removal.
Rockefeller University Press has partnered with Cashmere to enable safe and transparent AI inference use of its journals, protecting authors' work while providing visibility and revenue transparency. The partnership uses Cashmere's infrastructure suite to manage AI-powered research applications.
Researchers at Columbia University Irving Medical Center have identified Sirtuin 1 as a key driver of neuroendocrine prostate cancer, an aggressive form of the disease. Genetic or pharmacological inhibition of Sirtuin 1 prevents tumor growth in mice and lays the groundwork for future clinical studies aimed at developing new treatments.
Researchers found that increases in macrophage cell volume reprogram gene expression and induce inflammation. Cell swelling also triggers an enhanced antiviral response in infected cells.
Researchers found that polyploid cells activate a stress signaling pathway causing increased mobility and engulfing neighboring cells. This behavior can promote tumor growth and therapy resistance in aggressive cancers.
Researchers developed first-in-class dual HIF inhibitors that, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice. The drugs target HIF-1/2 transcription factors, which are key regulators of cancer progression.
Researchers discovered that targeting the Dectin-1 receptor can restore functional pathways of dysfunctional immune cells like Tregs, offering a promising novel therapeutic avenue for treating allergic asthma. The study showed that this approach can reduce airway inflammation and renew immunoregulatory capacity.
Researchers have identified TIE2 as a crucial link between two signaling pathways that drive the growth of blood vessel abnormalities in the brain. Inhibiting TIE2 with a small drug called rebastinib may provide an endothelial cell-centered approach to prevent CCMs, which can cause brain hemorrhages and seizures.
Researchers found that macrophages retain memories of previous infections due to persistent signaling molecules left behind, which can be reversed by blocking cytokine signaling pathways. This discovery suggests new ways to reduce the activity of misprogrammed macrophages contributing to autoimmune diseases.
Researchers have discovered that amyloid-β deposits in preeclamptic placentas can disrupt placenta formation, leading to the development of high blood pressure and organ damage. The study found that these deposits impair the ability of placental cells to undergo syncytialization, a critical step in placenta formation.
Researchers identified a way to suppress daily fluctuations in immune cells' activity, which may prevent tissue damage during daylight hours. A drug that targets neutrophils was found to alleviate inflammation and protect against infections.
Researchers developed a lyophilized open-source RT-LAMP assay for pathogen detection, making diagnostics more accessible and affordable globally. The assay is heat stable, requires no cold chain, and can detect various pathogens with high sensitivity.
Researchers discover how cigarette smoke alters the function of mucosal-associated invariant T (MAIT) cells, a key type of immune cell in the lungs. This impairment increases susceptibility to respiratory infections and worsens chronic obstructive pulmonary disease (COPD).
The International Alliance for Primary Immunodeficiency Societies has partnered with Rockefeller University Press to launch the Journal of Human Immunity, an open-access journal focused on human immunity and inborn errors of immunity. The journal aims to provide a platform for groundbreaking research and attract top-tier submissions.
Researchers developed artificial lymphoid organ-chips to recreate human immune system's response to booster vaccines. The technology could potentially be used to evaluate the likely effectiveness of new protein and mRNA-based booster vaccines for COVID-19 and other infectious diseases.
Researchers discovered a parasite protein that enhances wound healing in mice by stimulating immune cells to promote tissue regeneration and inhibit scarring. The protein, TGM, accelerates wound closure and improves skin regeneration.
Researchers discovered that Huntington's disease protein aggregates cause breaks in the nuclear envelope, leading to DNA damage and misregulation of neuronal genes. The study suggests a common mechanism for neurodegenerative diseases involving nuclear aggregate-induced ruptures.
Researchers found that frequent respiratory infections in children may have elevated their innate immune activity, protecting them from severe COVID-19 symptoms. The study suggests that childhood exposure to common cold viruses and bacteria boosted the kids' immune systems, allowing them to better fight off SARS-CoV-2.
Researchers have discovered a new way to inhibit immune cells that drive allergic asthma by targeting the Piezo1 protein. The study found that switching on Piezo1 channels can reduce lung inflammation and alleviate symptoms of airway hyperreactivity in mice with ILC2-dependent airway inflammation.
Researchers identified a yeast that can displace Candida albicans, preventing invasive candidiasis. The novel yeast Kazachstania weizmannii lives harmlessly in intestines and competes with C. albicans for space, reducing its population.
Researchers identified TLR9 as a key receptor in central tolerance, the process that eliminates self-reactive B cells. Depleting TLR9 impairs this process, leading to increased antibody production and autoimmune disease. Neutralizing CXCL4 may restore B cell tolerance, offering new therapeutic strategies.
Researchers found that mutations in blood stem cells can promote the development of colitis-associated colon cancer (CAC) by increasing blood vessel formation. Blocking certain drugs, such as axitinib, inhibited CAC tumor growth in mice with clonal hematopoiesis, suggesting potential therapeutic strategies.
Researchers found that bats lose their hearing in old age due to exposure to high noise levels in their colonies. The study suggests that bats may have evolved adaptations to cope with these noisy environments, which could provide insights into human age-related hearing loss.
Researchers have successfully restored vision in mice with retinitis pigmentosa using a new CRISPR-based genome editing technique. The PE SpRY system corrected genetic mutations and restored normal electrical responses to light, preserving vision into old age. This breakthrough offers potential for treating inherited blindness.
Researchers at Memorial Sloan Kettering Cancer Center discovered that common cancer treatments cause long-term damage to heart tissue by activating a key inflammatory signaling pathway. Inhibiting this pathway may reduce the risk of cancer survivors developing heart disease later in life.
A team of researchers found that aged mice infected with SARS-CoV-2 exhibited impaired type I interferon signaling and reduced levels of type II interferon IFN-γ, leading to increased susceptibility to severe disease. Treatment with IFN-γ protected these animals from severe illness.
Researchers found that inhibiting GABA A receptors protects intestinal stem cells from chemotherapy and radiotherapy-induced damage, reducing DNA damage and increasing survival. Flumazenil, an FDA-approved anti-sedative, shows promise in protecting the intestine from these toxic effects.
Researchers found that increasing new neurons in mice with AD rescues their memory defects by restoring neural circuits and dendritic spines. Boosting neurogenesis may be a viable strategy to treat AD patients.
Researchers at Stanford University developed a custom molecule sBCMA-Fc V3 that inhibits the growth of both multiple myeloma and diffuse large B cell lymphoma in mice. The molecules were found to be nontoxic in monkeys, suggesting they could be used to treat humans with these deadly diseases.
Researchers have identified two broadly neutralizing antibodies that can effectively neutralize all SARS-CoV-2 variants, including Omicron BA.1 and BA.2 subtypes. The antibodies, Cv2.1169 and Cv2.3194, were found to be fully active against Alpha, Beta, Gamma, and Delta variants.
Researchers have discovered that cancer cells carrying a common mutation accumulate large amounts of ferrous iron, which can be exploited to deliver powerful anticancer drugs. The therapeutic strategy could treat various cancers driven by KRAS mutations.
Researchers report successful treatment of two young infants with PROS using breast cancer drug alpelisib, inducing rapid and significant clinical improvement in symptoms. The treatment was well-tolerated and showed promising results, supporting the use of low-dose alpelisib in these patients.
Researchers have discovered a new therapeutic approach that prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state. The drug C26 activates NR2F1, a protein that can induce cancer cell dormancy and prevent recurrence and metastasis.
A Yale team has discovered an RNA molecule, SLR14, that stimulates the body's early antiviral defense system to protect against SARS-CoV-2 variants. This therapy holds promise as a new class of RNA therapeutics for treating COVID-19 in immunocompromised patients.
Researchers in Japan developed a vaccination approach that promotes the production of antibodies neutralizing SARS-CoV-2 and other coronaviruses. The new strategy involves genetically engineering the spike protein receptor-binding domain to shield its head region, boosting antibody production against the core region.
Researchers have discovered that toxic animals produce 'toxin sponges' to mop up deadly toxins and prevent them from binding to vital proteins. This alternative autoresistance strategy may offer a general means of toxin protection, including the development of antidotes against various toxic agents.
A recent study discovered that brain cells cannot maintain the myelin sheath in the absence of the TDP-43 protein. Restoring cholesterol levels has been proposed as a potential therapeutic strategy for neurodegenerative diseases associated with TDP-43. The research found that oligodendrocytes, responsible for producing myelin, have def...
Researchers at Weill Cornell Medicine have discovered that injecting mice with pulmonary endothelial cells can reverse the symptoms of emphysema. The study found that targeting endothelial cell function may represent a strategy for treating patients with advanced COPD or emphysema. Injecting healthy lung endothelial cells and/or inhibi...
Researchers have identified a pair of microRNAs that help maintain breast cancer stem cells and drive tumor growth. Targeting these microRNAs may improve the prognosis of patients with aggressive forms of breast cancer by making cancer stem cells more susceptible to chemotherapy.
Researchers found that tumors with a softer matrix are more resistant to treatment, activating signaling pathways that promote cell survival. Targeting this pathway could enhance the effectiveness of chemo- and radiotherapy.
Researchers have identified a new molecular target, MDM4, that could potentially treat idiopathic pulmonary fibrosis (IPF) by initiating a genetic program to remove scar tissue from the lungs. Targeting this protein may prevent respiratory failure and improve treatment options for patients with IPF.
A new drug has been identified that can prevent Alzheimer's disease by modulating the enzyme involved in forming amyloid plaques. The drug was tested on rodents and monkeys, demonstrating safety and effectiveness in reducing Aβ42 production and plaque formation.
A new study suggests that individuals who remain asymptomatic after SARS-CoV-2 infection have a highly efficient and balanced anti-viral cellular response. This response produces a careful balance of pro- and anti-inflammatory molecules, protecting the host without causing symptoms.
Researchers at McGill University identified a new cellular pathway controlling cell surface receptor proteins that limits brain tumor growth and spread. Restoring the activity of Rab35, a protein involved in this pathway, may be a new therapeutic strategy for glioblastoma.
A recent study published in the Journal of Experimental Medicine found that SARS-CoV-2 can directly infect brain cells, leading to devastating consequences such as localized ischemia and cell death. The researchers also discovered that the virus's ability to invade the central nervous system may be related to its neurological symptoms.
Researchers found that combining CAR T cells with a proinflammatory environment created by STING pathway activation can improve their ability to attack tumor cells. This approach, combined with therapeutic antibodies, led to the complete eradication of breast tumors in mice.
A study published in the Journal of Experimental Medicine reveals that inhibiting protein OCA-B protects mice from type 1 diabetes by limiting immune cell activity. The finding provides a proof-of-principle for OCA-B as a therapeutic target and could lead to further development of treatments.
Researchers found that pairs of antibodies targeting different parts of the viral spike protein can prevent or treat SARS-CoV-2 infection at lower doses than single antibodies. This approach may help reduce the chance of the virus mutating and becoming resistant to antibody treatments.